GLORIFINO JUAN: Open Payments
NPI 1548997422 · FRENCH CAMP, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,629 in 32 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $547 · 2025 $1,629
Food & beverage: $1,629
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $434 |
| AstraZeneca Pharmaceuticals LP | 6 | $259 |
| Corcept Therapeutics | 3 | $230 |
| Novo Nordisk Inc | 3 | $199 |
| Amgen Inc. | 5 | $165 |
| GENZYME CORPORATION | 1 | $141 |
| Axsome Therapeutics, Inc. | 1 | $104 |
| Lilly USA, LLC | 3 | $62 |
| GlaxoSmithKline, LLC. | 1 | $20 |
| PFIZER INC. | 1 | $15 |
Products named: Kerendia, Korlym, Ozempic, DUPIXENT, BREZTRI, AIRSUPRA, Auvelity, REPATHA.
Industry payments across CA — which companies pay providers there.
